Inventor
LI GONG
CN13 patents
⚠️ This page may combine multiple inventors who share the name “LI GONG”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
BEIJING TIDE PHARMACEUTICAL CO LTD
10 patentsUS10323023B2Jun 18, 2019
Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof
BEIJING TIDE PHARMACEUTICAL CO LTD14 citations85
US11919918B2Mar 5, 2024
P2X3 andor P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof
BEIJING TIDE PHARMACEUTICAL CO LTD6 citations84
US11390609B2Jul 19, 2022
Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof
BEIJING TIDE PHARMACEUTICAL CO LTD12 citations84
US10329282B2Jun 25, 2019
Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof
BEIJING TIDE PHARMACEUTICAL CO LTD13 citations83
US11414444B2Aug 16, 2022
P2X3 and/or P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof
BEIJING TIDE PHARMACEUTICAL CO LTD5 citations82
US12509479B2Dec 30, 2025
P2X3 and/or P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof
BEIJING TIDE PHARMACEUTICAL CO LTD0 citations61
US11939578B2Mar 26, 2024
Double-stranded RNA molecule targeting CKIP-1 and use thereof
BEIJING TIDE PHARMACEUTICAL CO LTD0 citations59
US11155819B2Oct 26, 2021
Double-stranded RNA molecule targeting CKIP-1 and use thereof
BEIJING TIDE PHARMACEUTICAL CO LTD0 citations59
US12398118B2Aug 26, 2025
Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and use thereof
BEIJING TIDE PHARMACEUTICAL CO LTD0 citations50
US11905274B2Feb 20, 2024
Receptor inhibitors, pharmaceutical compositions comprising the same and use thereof
BEIJING TIDE PHARMACEUTICAL CO LTD0 citations50